These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26282478)

  • 21. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
    Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
    Antohe I; Antoniu SA; Gavrilovici C
    Expert Opin Pharmacother; 2018 Feb; 19(3):287-289. PubMed ID: 29271268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium.
    Hussar DA; Ahmad A
    J Am Pharm Assoc (2003); 2013; 53(6):662-70. PubMed ID: 24185435
    [No Abstract]   [Full Text] [Related]  

  • 24. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R; Norris V; Siederer S
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.
    Adamson PD; Anderson JA; Brook RD; Calverley PMA; Celli BR; Cowans NJ; Crim C; Dixon IJ; Martinez FJ; Newby DE; Vestbo J; Yates JC; Mills NL
    J Am Coll Cardiol; 2018 Sep; 72(10):1126-1137. PubMed ID: 30165984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
    Blair HA; Deeks ED
    Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rogliani P; Rinaldi B; Cazzola M
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):35-41. PubMed ID: 25382021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fixed combination of long-acting bronchodilators in COPD].
    Steurer J
    Praxis (Bern 1994); 2015 Oct; 104(22):1221. PubMed ID: 26953373
    [No Abstract]   [Full Text] [Related]  

  • 32. The stability of blood Eosinophils in chronic obstructive pulmonary disease.
    Long GH; Southworth T; Kolsum U; Donaldson GC; Wedzicha JA; Brightling CE; Singh D
    Respir Res; 2020 Jan; 21(1):15. PubMed ID: 31924207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
    Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
    Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
    Stanbrook MB
    Ann Intern Med; 2015 Dec; 163(12):JC10. PubMed ID: 26666800
    [No Abstract]   [Full Text] [Related]  

  • 38. What to use INSTEAD of inhaled corticosteroids in COPD?
    Calverley PM
    Eur Respir J; 2014 Dec; 44(6):1391-3. PubMed ID: 25435522
    [No Abstract]   [Full Text] [Related]  

  • 39. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF; Singh D; Munzu C; Kilbride S; Church A
    Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.